CXCR4 and Miyoshi myopathy: At the same time, relevant studies [140,141] also showed that the CXCR4-targeted inhibitor Plerixafor combined with bortezomib could be used as a chemotherapy sensitization strategy for relapsed/refractory MM, with good safety and a high objective remission rate.